Symbols

SGMT

Sagimet Biosciences·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 2

Consensus Rating "Strong Buy"

Gap Down

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SGMT

Sagimet Biosciences Inc.

A clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN)

Industry

Pharmaceutical

Established Date

12/19/2006

Listing Date

07/14/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.sagimet.com

Security Type

Common stock

Office address

155 Bovet Road, Suite 303, San Mateo, California 94402

Business

Introduction

Sagimet Biosciences Inc., was incorporated in Delaware on December 19, 2006. The company is a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors for the metabolic and fibrotic pathways. Its lead drug candidate, denifanstat, is an oral selective FASN inhibitor that is being developed for the treatment of metabolic dysfunction-associated steatohepatitis, acne and certain cancers.

Company Financials

EPS

SGMT has released its 2025 Q4 earnings. EPS was reported at -0.29, versus the expected -1.2, beating expectations. The chart below visualizes how SGMT has performed over recent quarters, highlighting trends in earnings surprises.